Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3586174 | 0.90 | LMNA (0.37) | LMNAKDM4EALDH1A1POLBMAPT | |
| SCHEMBL1178676 | 0.82 | CYP19A1 (0.39) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL28953772 | 0.81 | MAPK1 (0.46) | KDM4EALDH1A1 | |
| SCHEMBL25854022 | 0.79 | NPC1 (0.43) | ALDH1A1MAPTCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL3275833 | 0.79 | CYP11B1 (0.43) | CYP11B1CYP11B2 | |
| SCHEMBL3629428 | 0.78 | CSNK2A2 (0.40) | LMNAKDM4EALDH1A1POLBMAPT | |
| SCHEMBL733483 | 0.76 | CSNK2A2 (0.46) | LMNAKDM4EALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL25311465 | 0.76 | CYP11B1 (0.38) | LMNAKDM4EALDH1A1POLBMAPT | |
| SCHEMBL3577086 | 0.75 | ALDH1A1 (0.41) | KDM4EALDH1A1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL20027346 | 0.74 | QPCT (0.38) | CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| EP-3901159-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3517112-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200085821-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3517112-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10335410-B2 | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180311239-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| US-9962386-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170216290-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-9683003-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170002032-A9 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160009744-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10335410-B2 | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | SAE1, SUMO1, SUMO3 | LMNA 2130/4885KDM4E 1160/4885ALDH1A1 1512/4885 |
| US-20170002032-A9 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | LMNA 2130/4885KDM4E 1160/4885ALDH1A1 1512/4885 |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | LMNA 2130/4885KDM4E 1160/4885ALDH1A1 1512/4885 |
| US-20170216290-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | LMNA 2130/4885KDM4E 1160/4885ALDH1A1 1512/4885 |
| US-20180311239-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | LMNA 2130/4885KDM4E 1160/4885ALDH1A1 1512/4885 |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | SAE1, SUMO1, SUMO3 | LMNA 2130/4885KDM4E 1160/4885ALDH1A1 1512/4885 |
| US-20220331316-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | LMNA 2130/4885KDM4E 1160/4885ALDH1A1 1512/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | LMNA 4877/4885KDM4E 3447/4885ALDH1A1 971/4885 |
| US-20200085821-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | LMNA 2130/4885KDM4E 1160/4885ALDH1A1 1512/4885 |
| US-20160009744-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | LMNA 2130/4885KDM4E 1160/4885ALDH1A1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.